These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 20663805)
1. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. Llorca PM J Psychopharmacol; 2010 Aug; 24(2 Suppl):21-6. PubMed ID: 20663805 [TBL] [Abstract][Full Text] [Related]
2. Restoring circadian rhythms: a new way to successfully manage depression. Gorwood P J Psychopharmacol; 2010 Aug; 24(2 Suppl):15-9. PubMed ID: 20663804 [TBL] [Abstract][Full Text] [Related]
3. Agomelatine: efficacy at each phase of antidepressant treatment. Kennedy SH CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725 [TBL] [Abstract][Full Text] [Related]
4. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. Kasper S; Hamon M World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935 [TBL] [Abstract][Full Text] [Related]
6. Treating each and every depressed patient. Kennedy SH J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279 [TBL] [Abstract][Full Text] [Related]
7. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Lemoine P; Guilleminault C; Alvarez E J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566 [TBL] [Abstract][Full Text] [Related]
8. Agomelatine: a preliminary review of a new antidepressant. Zupancic M; Guilleminault C CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278 [TBL] [Abstract][Full Text] [Related]
9. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. Kennedy SH; Rizvi SJ CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279 [TBL] [Abstract][Full Text] [Related]
10. Agomelatine, a melatonin agonist with antidepressant properties. Dubovsky SL; Warren C Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703 [TBL] [Abstract][Full Text] [Related]
14. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. Lam RW J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806 [TBL] [Abstract][Full Text] [Related]
15. A benefit-risk assessment of agomelatine in the treatment of major depression. Howland RH Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Rouillon F Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938 [TBL] [Abstract][Full Text] [Related]
17. Clinical studies on the efficacy of agomelatine on depressive symptoms. Goodwin GM CNS Drugs; 2009; 23 Suppl 2():35-9. PubMed ID: 19708724 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Stein DJ; Picarel-Blanchot F; Kennedy SH Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747 [TBL] [Abstract][Full Text] [Related]
19. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. Goodwin GM; Emsley R; Rembry S; Rouillon F; J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920 [TBL] [Abstract][Full Text] [Related]